Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study

Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study

Abstract Background Biliary tract cancer (BTC) is a dismal disease, even after curative intent surgery. We conducted this prospective, non-randomized phase II study to evaluate the feasibility and efficacy of cisplatin and gemcitabine as adjuvant treatment in patients with resected BTC. Methods Pati...

Full description

Bibliographic Details
Main Authors: Alexander R. Siebenhüner, Heike Seifert, Helga Bachmann, Burkhardt Seifert, Thomas Winder, Jonas Feilchenfeldt, Stefan Breitenstein, Pierre-Alain Clavien, Roger Stupp, Alexander Knuth, Bernhard Pestalozzi, Panagiotis Samaras
Format: Article
Language:English
Published: BMC 2018-01-01
Series:BMC Cancer
Subjects:
Adjuvant chemotherapy
Biliary tract cancer
Cholangiocellular carcinoma
Gallbladder cancer
Cisplatin and gemcitabine
Feasibility
Online Access:http://link.springer.com/article/10.1186/s12885-017-3967-0

Internet

http://link.springer.com/article/10.1186/s12885-017-3967-0

Similar Items